Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs Viatris Inc — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73.18, while Viatris Inc trades at $17.21 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while JPMorgan Diversified Return International Eqty ETF pays none, and Viatris Inc is trading nearer its 52-week high, JPMorgan Diversified Return International Eqty ETF nearer its low. Which is the better fit depends on your goals.
| JPIN | VTRS | |
|---|---|---|
52-Week High | $76.96 | $17.39 |
52-Week Low | $63.14 | $8.74 |
Market Cap | — | $19.79B |
Sector | — | Health |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN trades at $73.11, down 0.5% on the day, with technical indicators showing a neutral to bearish bias. The ETF lacks disclosed fundamental ratios, and a dividend of $0.91 is scheduled for June 2026. Recent coverage highlights its smart beta approach to international equity exposure since its 2014 launch.
The outlook remains neutral amid mixed technical signals and absent fundamental data. Risks include reliance on international markets and valuation opacity. Investor sentiment is cautious without clear earnings metrics or analyst consensus, requiring due diligence on underlying holdings and strategy.
Viatris (VTRS) trades at $17.10, down 1.1% today but maintains a bullish technical outlook with strong moving average signals. The company shows mixed fundamentals with recent earnings beats but negative profitability metrics, while analyst consensus leans toward Hold with a $20 price target. Recent positive developments include FDA acceptance of new drug applications and pipeline progress in biosimilars.
Viatris presents a value opportunity with reasonable P/S and P/B ratios, but faces challenges with negative margins and high debt. The stock's upside potential depends on successful pipeline execution and debt reduction, while risks include competitive pressures and execution missteps in a challenging pharmaceutical market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
